Inactive Instrument

Other languages Tiger X Medical Inc Other OTC

Equities

US88677A1043

End-of-day quote Other OTC Other stock markets
- ^USD	-

05-21	BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	MT
05-14	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	05-21
BioCardia Announces Reverse Stock Split	05-21
Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
BioCardia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14
BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	05-14
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	05-09
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	05-01
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	05-01
Transcript : BioCardia, Inc. - Special Call	04-30
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	04-25
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	04-25
Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024	03-27
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	03-27
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	03-20
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	03-13
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	03-13
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	03-12
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	03-12
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	03-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tiger X Medical Inc Other OTC

Equities

US88677A1043

Other languages

Filters